323 related articles for article (PubMed ID: 37448553)
21. OX40L-Armed Oncolytic Virus Boosts T-cell Response and Remodels Tumor Microenvironment for Pancreatic Cancer Treatment.
Liu S; Li F; Ma Q; Du M; Wang H; Zhu Y; Deng L; Gao W; Wang C; Liu Y; Zhao Z; Liu H; Wang R; Tian Y; Hu M; Wan Y; Lu W; Zhang M; Zhao M; Cao Y; Zhang H; Wang W; Wang H; Wang Y
Theranostics; 2023; 13(12):4016-4029. PubMed ID: 37554264
[No Abstract] [Full Text] [Related]
22. Combination of gemcitabine and anti-PD-1 antibody enhances the anticancer effect of M1 macrophages and the Th1 response in a murine model of pancreatic cancer liver metastasis.
Ho TTB; Nasti A; Seki A; Komura T; Inui H; Kozaka T; Kitamura Y; Shiba K; Yamashita T; Yamashita T; Mizukoshi E; Kawaguchi K; Wada T; Honda M; Kaneko S; Sakai Y
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33188035
[TBL] [Abstract][Full Text] [Related]
23. Macrophage-Derived Granulin Drives Resistance to Immune Checkpoint Inhibition in Metastatic Pancreatic Cancer.
Quaranta V; Rainer C; Nielsen SR; Raymant ML; Ahmed MS; Engle DD; Taylor A; Murray T; Campbell F; Palmer DH; Tuveson DA; Mielgo A; Schmid MC
Cancer Res; 2018 Aug; 78(15):4253-4269. PubMed ID: 29789416
[TBL] [Abstract][Full Text] [Related]
24. Local and systemic immune profiles of human pancreatic ductal adenocarcinoma revealed by single-cell mass cytometry.
Brouwer TP; de Vries NL; Abdelaal T; Krog RT; Li Z; Ruano D; Fariña A; Lelieveldt BPF; Morreau H; Bonsing BA; Vahrmeijer AL; Koning F; de Miranda NFCC
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35793870
[TBL] [Abstract][Full Text] [Related]
25. TGFβ-derived immune modulatory vaccine: targeting the immunosuppressive and fibrotic tumor microenvironment in a murine model of pancreatic cancer.
Perez-Penco M; Weis-Banke SE; Schina A; Siersbæk M; Hübbe ML; Jørgensen MA; Lecoq I; Lara de la Torre L; Bendtsen SK; Martinenaite E; Holmström MO; Madsen DH; Donia M; Ødum N; Grøntved L; Andersen MH
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600556
[TBL] [Abstract][Full Text] [Related]
26. Expression and role of the immune checkpoint regulator PD-L1 in the tumor-stroma interplay of pancreatic ductal adenocarcinoma.
Daunke T; Beckinger S; Rahn S; Krüger S; Heckl S; Schäfer H; Wesch D; Pilarsky C; Eckstein M; Hartmann A; Röcken C; Wandmacher AM; Sebens S
Front Immunol; 2023; 14():1157397. PubMed ID: 37449210
[TBL] [Abstract][Full Text] [Related]
27. Stromal HIF2 Regulates Immune Suppression in the Pancreatic Cancer Microenvironment.
Garcia Garcia CJ; Huang Y; Fuentes NR; Turner MC; Monberg ME; Lin D; Nguyen ND; Fujimoto TN; Zhao J; Lee JJ; Bernard V; Yu M; Delahoussaye AM; Jimenez Sacarello I; Caggiano EG; Phan JL; Deorukhkar A; Molkentine JM; Saur D; Maitra A; Taniguchi CM
Gastroenterology; 2022 Jun; 162(7):2018-2031. PubMed ID: 35216965
[TBL] [Abstract][Full Text] [Related]
28. Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options.
Kabacaoglu D; Ciecielski KJ; Ruess DA; Algül H
Front Immunol; 2018; 9():1878. PubMed ID: 30158932
[TBL] [Abstract][Full Text] [Related]
29. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
[TBL] [Abstract][Full Text] [Related]
30. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
Front Immunol; 2021; 12():648917. PubMed ID: 33777046
[No Abstract] [Full Text] [Related]
31. CD73 and PD-L1 dual blockade amplifies antitumor efficacy of SBRT in murine PDAC models.
Ye J; Gavras NW; Keeley DC; Hughson AL; Hannon G; Vrooman TG; Lesch ML; Johnston CJ; Lord EM; Belt BA; Linehan DC; Eyles J; Gerber SA
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37142292
[TBL] [Abstract][Full Text] [Related]
32. PI3K/mTOR inhibition induces tumour microenvironment remodelling and sensitises pS6
De Wispelaere W; Annibali D; Tuyaerts S; Messiaen J; Antoranz A; Shankar G; Dubroja N; Herreros-Pomares A; Baiden-Amissah REM; Orban MP; Delfini M; Berardi E; Van Brussel T; Schepers R; Philips G; Boeckx B; Baietti MF; Congedo L; HoWangYin KY; Bayon E; Van Rompuy AS; Leucci E; Tabruyn SP; Bosisio F; Mazzone M; Lambrechts D; Amant F
Clin Transl Med; 2024 May; 14(5):e1655. PubMed ID: 38711203
[TBL] [Abstract][Full Text] [Related]
33. Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironment.
Falcomatà C; Bärthel S; Widholz SA; Schneeweis C; Montero JJ; Toska A; Mir J; Kaltenbacher T; Heetmeyer J; Swietlik JJ; Cheng JY; Teodorescu B; Reichert O; Schmitt C; Grabichler K; Coluccio A; Boniolo F; Veltkamp C; Zukowska M; Vargas AA; Paik WH; Jesinghaus M; Steiger K; Maresch R; Öllinger R; Ammon T; Baranov O; Robles MS; Rechenberger J; Kuster B; Meissner F; Reichert M; Flossdorf M; Rad R; Schmidt-Supprian M; Schneider G; Saur D
Nat Cancer; 2022 Mar; 3(3):318-336. PubMed ID: 35122074
[TBL] [Abstract][Full Text] [Related]
34. Loss of Rnf43 Accelerates Kras-Mediated Neoplasia and Remodels the Tumor Immune Microenvironment in Pancreatic Adenocarcinoma.
Hosein AN; Dangol G; Okumura T; Roszik J; Rajapakshe K; Siemann M; Zaid M; Ghosh B; Monberg M; Guerrero PA; Singhi A; Haymaker CL; Clevers H; Abou-Elkacem L; Woermann SM; Maitra A
Gastroenterology; 2022 Apr; 162(4):1303-1318.e18. PubMed ID: 34973294
[TBL] [Abstract][Full Text] [Related]
35. A nanodrug simultaneously inhibits pancreatic stellate cell activation and regulatory T cell infiltration to promote the immunotherapy of pancreatic cancer.
Wang R; Hong K; Zhang Q; Cao J; Huang T; Xiao Z; Wang Y; Shuai X
Acta Biomater; 2023 Oct; 169():451-463. PubMed ID: 37572982
[TBL] [Abstract][Full Text] [Related]
36. Interplay between MAP kinases and tumor microenvironment: Opportunity for immunotherapy in pancreatic cancer.
Kumar S; Singh SK; Srivastava P; Suresh S; Rana B; Rana A
Adv Cancer Res; 2023; 159():113-143. PubMed ID: 37268394
[TBL] [Abstract][Full Text] [Related]
37. Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint antibody therapy in mice.
Smith JP; Wang S; Nadella S; Jablonski SA; Weiner LM
Cancer Immunol Immunother; 2018 Feb; 67(2):195-207. PubMed ID: 29043413
[TBL] [Abstract][Full Text] [Related]
38. A DNA Hypomethylating Drug Alters the Tumor Microenvironment and Improves the Effectiveness of Immune Checkpoint Inhibitors in a Mouse Model of Pancreatic Cancer.
Gonda TA; Fang J; Salas M; Do C; Hsu E; Zhukovskaya A; Siegel A; Takahashi R; Lopez-Bujanda ZA; Drake CG; Manji GA; Wang TC; Olive KP; Tycko B
Cancer Res; 2020 Nov; 80(21):4754-4767. PubMed ID: 32816859
[TBL] [Abstract][Full Text] [Related]
39. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.
Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L
J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479
[TBL] [Abstract][Full Text] [Related]
40. CDK1/2/5 inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer.
Huang J; Chen P; Liu K; Liu J; Zhou B; Wu R; Peng Q; Liu ZX; Li C; Kroemer G; Lotze M; Zeh H; Kang R; Tang D
Gut; 2021 May; 70(5):890-899. PubMed ID: 32816920
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
